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Abstract
Background: Smoking is the leading preventable cause of death in the United States, but evidence-based smoking
cessation therapy is underutilized. Financial incentive strategies represent an innovative approach for increasing the
use of counseling and pharmacotherapy. If effective, they could supplement or supplant resource-intensive policy
options, particularly in populations for whom smoking has substantial societal costs. FIESTA (Financial IncEntives for
Smoking TreAtment) will randomize hospitalized smokers to receive usual smoking cessation care alone or usual
smoking care augmented with financial incentives. We aim to compare the impact of these two strategies on 1)
smoking abstinence, 2) use of counseling and nicotine replacement therapy, and 3) quality of life of participants.
We also will evaluate the short-term and long-term return on the investment of incentives. The FIESTA Oral
Microbiome Substudy will compare the oral microbiome of smokers and nonsmokers to longitudinally assess
whether smoking cessation changes oral microbiome composition.
Methods: We will enroll 182 inpatient participants from the Manhattan campus of the Veterans Affairs New York
Harbor Healthcare System. All participants receive enhanced usual care, including screening for tobacco use,
counseling while hospitalized, access to nicotine replacement therapy, and referral to a state Quitline. Patients in
the financial incentive arm receive enhanced usual care and up to $550 for participating in the New York Smoker’s
Quitline, using nicotine replacement therapy (NRT), and achieving biochemically confirmed smoking cessation at
2 months and 6 months. In the microbiome substudy, we enroll nonsmoking control participants matched to each
recruited smoker’s hospital ward, sex, age, diabetes status, and antibiotic use. After discharge, participants are asked
to complete periodic phone interviews at 2 weeks, 2 months, 6 months, and 12 months and provide expired
carbon monoxide and saliva samples at 2 months, 6 months, and 12 months for cotinine testing and oral
microbiome analysis.
Discussion: The incentive interventions of FIESTA may benefit hospitalized smokers, an objective made all the more
critical because smoking rates among hospitalized patients are higher than those in the general population. Moreover,
the focus of FIESTA on evidence-based therapy and bioconfirmed smoking cessation can help guide policy efforts to
reduce smoking-related healthcare costs in populations with high rates of tobacco use and costly illnesses.
Trial registration: ClinicalTrials.gov, NCT02506829. Registered on 1 July 2014.
Keywords: FIESTA, Smoking cessation, Manhattan VA Hospital, Financial incentives, Veterans
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Background
Smoking is the leading preventable cause of death and
disease in the United States [1], and most adults who
continue to smoke are disproportionately low-income or
have no college education [2]. While 70% of smokers ex-
press the desire to quit [3], only 25% of those individuals
seek assistance with smoking cessation and an even
smaller proportion use evidence-based methods [4], such
as behavioral counseling or pharmacotherapy [5].
Among hospitalized patients, tobacco dependence treat-
ment is particularly critical because persistent smoking
increases the risk of future smoking-related illnesses,
such as coronary heart disease, cerebrovascular disease,
emphysema, and cancer [1, 6].
Financial incentives for smoking cessation may be an ef-
fective strategy for increasing the use of evidence-based ces-
sation therapy among hospitalized patients [7–10]. Based on
principles from microeconomic theory, financial incentives
influence individual behavior and decision-making because
individuals are motivated by the prospect of welfare gains.
While evidence is mixed, some incentive interventions have
been effective in the treatment of obesity [11], diabetes [12],
and smoking at the worksite [9]. Incentives may be particu-
larly effective when designed to leverage concepts from be-
havioral economics, such as immediacy of payments and
framing of missed payments with regret aversion [7, 8, 13–
17]. If effective, financial incentive programs could supple-
ment or supplant other policy options for smoking cessa-
tion, particularly in populations for whom smoking has
substantial societal costs. In addition, because health in-
surers are increasingly adopting bundled payment systems
and smokers generally incur high healthcare costs [8, 13,
18], financial incentives may be sustainable due to their po-
tentially favorable return on investment [14, 15]. The effect-
iveness of financial incentives for increasing smoking
cessation among hospitalized patients is unknown.
In addition to the potential effectiveness of incentives
for smoking cessation, another scientific area of growing
relevance to smokers is the oral microbiome. Smokers
have higher levels of oral mutagens and carcinogens,
and this may contribute to their increased risk of oral
cancer. It is also known that quitting smoking reduces
the risk of developing oral cancer [19]. Recent research
has suggested that a mechanism explaining the associ-
ation of smoking and oral cancer may involve activation
of carcinogens deposited through smoking by oral bac-
teria [20]. However, little is known about how smoking
cessation affects the oral microbiome of smokers.
Objectives
The primary objective of the Financial IncEntives for
Smoking TreAtment (FIESTA) trial is to compare the ef-
fects of two approaches for smoking cessation—financial
incentives plus enhanced usual care versus enhanced
usual care alone—on smoking abstinence, use of
evidenced-based therapy, and quality of life. The second
objective is to estimate the short-term and long-term re-
turn on investment of using financial incentives to pro-
mote smoking cessation. In addition, the FIESTA Oral
Microbiome Substudy will be conducted to determine
whether smoking cessation changes the oral microbiome
composition of smokers.
We hypothesize that participants in the financial in-
centives arm will experience higher rates of smoking
cessation, improved quality of life, and lower rates of
financial distress, and that these gains will be associated
with a favorable return on investment. We also
hypothesize that patients experiencing greater financial
distress at baseline will be more likely to stop smoking
in response to financial incentives. Our oral microbiome
hypothesis is that smoking cessation will lead to changes
in the microbiome that increase its similarity to the
microbiome of nonsmokers.
Methods/design
Overall design
The trial is sponsored by the Robert Wood Johnson
Foundation. We will enroll 182 inpatient participants
from the Manhattan campus of the Veterans Affairs
(VA) New York Harbor Healthcare System. After con-
ducting a baseline survey of the sociodemographic and
clinical characteristics of participants and administering
a Stages of Change questionnaire, smokers are random-
ized to the financial incentives plus enhanced usual care
arm or the enhanced usual care alone arm with an allo-
cation ratio of 1:1. All participants receive enhanced
usual care, which includes tobacco use screening, coun-
seling while hospitalized, hospital-directed educational
materials on quitting smoking, nicotine replacement
therapy (NRT) at the discretion of inpatient healthcare
providers, and referral to a state Quitline (this compo-
nent represents the enhancement). The components of
enhanced usual care were selected based on prior evi-
dence for effective smoking cessation interventions. In
addition to enhanced usual care, smokers who are ran-
domized to the financial incentives arm are also eligible
to receive up to $550 for participating in counseling
(both community-based counseling and state Quitline
counseling), using smoking cessation pharmacotherapy,
and biochemically confirmed smoking cessation at
2 months and 6 months. The incentive schedule is sum-
marized in Table 1, and Figs. 1 and 2 display brochures
provided to participants in the enhanced usual care arm
or the financial incentives plus enhanced usual care arm.
After discharge, smokers are asked to complete periodic
phone interviews for 12 months to assess patient-reported
smoking cessation, use of evidence-based cessation inter-
ventions, and quality of life. All participants are also asked
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to provide saliva samples for 12 months for both cotinine
testing and oral microbiome analysis. Smoking status at
6 months, as determined by salivary cotinine analysis, is
used to determine whether a patient is considered a per-
sistent smoker or a past smoker because rates of recidiv-
ism are low after 6 months [21], while many patients who
quit smoking immediately after being hospitalized soon
relapse [16]. An outline of enrollment, intervention, and
assessment can be found in the SPIRIT figure (Fig. 3) and
SPIRIT checklist (Additional file 1).
Study population
The VA Hospital in Manhattan is a New York University
(NYU) School of Medicine-affiliated teaching facility. The
institution predominately serves low-income veterans that
reside in Manhattan or its surrounding regions. The low
socioeconomic status of most participants in this trial may
limit the generalizability of our findings to other socioeco-
nomic groups within the United States and elsewhere.
Each year, approximately 4000 patients are admitted to its
medical and surgical services, while another approxi-
mately 1000 patients are admitted to its psychiatry service.
Roughly 60% of hospitalized patients at the Manhattan
VA are Caucasian, 31% are African American, and 17%
are Hispanic or Latino. Furthermore, about 61% of these
patients have only a high school education or less. The in-
stitution routinely cares for patients with acute myocardial
infarction, congestive heart failure, pneumonia, and
chronic obstructive pulmonary disease—all conditions as-
sociated with smoking.
Table 1 Schedule of financial incentives
Activity Time point Incentive
Speaking with a coach from the NYS Smoker’s Quitline 2 weeks $50
Completion of community-based smoking cessation program 2 weeks $50
Use of pharmacotherapy for smoking cessation 2 weeks $50
Smoking cessation (self-report + salivary cotinine) 2 months $150
Smoking cessation (self-report + salivary cotinine) 6 months $250
Fig. 1 Brochure provided to participants in enhanced usual care arm summarizing time points for follow-up and compensation. NRT nicotine
replacement therapy, VA Veteran’s Affairs
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Eligibility criteria
The criteria for hospitalized patients considered for en-
rollment in FIESTA are: 1) ≥ 18 years of age; 2) smoked
tobacco during the 30 days prior to hospitalization; 3)
possess an active US phone number; 5) not pregnant or
breastfeeding; 6) reside in the NYC area or have the abil-
ity to return to the Manhattan VA for at least 1 year; 7)
contemplating smoking cessation as assessed by readi-
ness to quit [22]; and 8) able to provide consent in Eng-
lish. Potential participants are excluded if they: 1) use
smokeless tobacco only; 2) are pregnant or breastfeed-
ing; 3) anticipate to be discharged to an institution (i.e.,
a nursing home or long-term care facility) at which the
patient will not have control over smoking rules; or 4)
are unable to provide informed consent.
Recruitment
The Veterans Information Systems and Technology Archi-
tecture (VISTA) program is used to gather information from
the Electronic Health Record (EHR) system (specifically
from nursing or physician admission assessments) to identify
hospitalized smokers who are eligible for participation. Each
day, an EHR-generated current smokers list is created and
used to recruit. Staff approach every potential participant to
describe the study, assess eligibility through the completion
of a screener, offer enrollment if eligible, complete a
Research Consent Form and HIPAA Release Form, and con-
duct a baseline survey and saliva collection. All electronic
data are kept in a password-protected and encrypted data-
base (REDCap) and each participant is assigned a study ID
number to separate their identifiable information from the
study records. Potential participants are also informed that
their participation is completely voluntary, and their consent
can be withdrawn at any time by providing staff with a letter
requesting they no longer be contacted.
The FIESTA Oral Microbiome Substudy will enroll both
smokers and hospitalized nonsmokers as controls. For
each smoker enrolled in FIESTA, staff will attempt to re-
cruit a matched nonsmoker using VISTA and electronic
chart review. Nonsmokers are matched based on: 1) age
within 10 years (if a match is identified in the first 30 days
after enrollment of the corresponding FIESTA participant)
or within 20 years (after the first 30 days); 2) sex; 3) ward
location; 4) antibiotic use; and 5) diabetes status. We will
relax the matching criterion based on diabetic status if we
are otherwise unable to identify a match.
The Computerized Patient Record System (CPRS) is
used to track the discharge information of participants
and to complete a chart abstraction 1 week post-
discharge. After discharge, smokers are referred to a
state Quitline (either New York or New Jersey) by re-
search staff and later contacted by a state Quitline
Fig. 2 Brochure provided to participants in financial incentives arm summarizing time points for follow-up and compensation. NRT nicotine
replacement therapy, VA Veteran’s Affairs
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counselor to discuss NRT, plans and strategies for quit-
ting, and other available smoking cessation resources.
Randomization
Smokers are randomized in a 1:1 ratio to either financial
incentives plus enhanced usual care or enhanced usual
care alone. We employ a computer-generated block
randomization design. Research staff implement the allo-
cation sequence using numbered, sealed envelopes that
are opened during participant enrollment. Because of the
nature of the intervention, participants are not blind to
their randomization into either the financial incentives
plus enhanced usual care or enhanced usual care groups.
Intervention
Smokers who are randomized into the financial incen-
tives plus enhanced usual care arm are eligible to receive
$550 for participating in counseling, using NRT, and
achieving biochemically confirmed smoking cessation at
2 months and 6 months (see Table 1). All participants
are compensated in US dollars (USD) using ClinCards, a
secure prepaid debit card system.
Research staff members are extensively trained in the
teach-back method in which study participants are asked to
repeat task-specific directions to staff to confirm under-
standing. The teach-back method has been shown to im-
prove instruction retention in patients postdischarge [23].
This instructional technique will be incorporated into the
FIESTA protocol to ensure that participants understand not
only the study aims and timeline, but have also compre-
hended the targets for which they are being incentivized.
Data collection and measurement of smoking cessation
outcomes
Participants are asked to complete an in-person survey
at enrollment and four follow-up interviews by phone at
Fig. 3 Schedule for enrollment, interventions, and assessments (SPIRIT figure)
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2 weeks, 2 months, 6 months, and 12 months. Each par-
ticipant receives $20 after completing surveys at each of
the follow-up time points. Each participant is also asked
to provide saliva samples at enrollment and at 2 months,
6 months, and 12 months, for which we provide a $50
payment to increase participation rates. The baseline
and follow-up surveys are similar in content and assess:
1) sociodemographic characteristics (i.e., demographics,
contact information, race/ethnicity, health literacy, exer-
cise habits, and nutrition habits) [24]; 2) smoking history
(i.e., smoking habits and home environment using ques-
tions adapted from the California Tobacco Survey [25],
nicotine dependence using questions adapted from the
Heaviness of Smoking Index [26], and smoking cessation
services received); 3) preference for incentive design
(goal-directed versus outcome-based); 4) participant
health (i.e., health status using the Veterans RAND
12-item Health Survey [27] and the EuroQol-5D [28–30]
to assess physical and mental functioning, alcohol-use
using the AUDIT-C [31, 32], marijuana use using the AS-
SIST, substance use using the self-administered Substance
Use Brief Screen [33], and depression using the PHQ-2
[34]); and 5) health services utilization in the prior
6 months. The baseline and follow-up surveys also meas-
ure treatment outcomes (i.e., 7-day and 30-day point
prevalence for smoking cessation, quit attempts, reduction
in daily smoking, changes in readiness to quit, and use of
NRT and Quitline counseling).
We collect saliva samples from each participant at
baseline, 2 months, 6 months, and 12 months. The sam-
ple is analyzed for cotinine—a biomarker that reflects
exposure to nicotine—using NicAlert kits to bioconfirm
smoking cessation, and the sample is also used to
characterize the oral microbiome. All participants also
undergo a carbon monoxide breath test at every saliva
collection. In addition, we ask each participant if they
have taken antibiotics in the 7 days prior to saliva collec-
tion or used NRT, e-cigarettes, or other forms of tobacco
in the 7 days prior to saliva collection. At 2 months, if a
participant reports tobacco abstinence, but is still using
NRT and the cotinine testing results in a value between
10 and 99 ng/mL, we use the carbon monoxide breath
test for biochemical validation. Research staff collect all
saliva samples in public locations convenient to the pa-
tient or at the Manhattan VA.
Research coordinators periodically audit study proce-
dures every 3 to 6 months to ensure implementation fi-
delity and adherence to the study protocol. Routine
re-training of research staff to reinforce study proce-
dures is performed every 6 to 9 months. This process is
performed independently of the investigators, but im-
pressions of study staff performance and feedback from
re-training exercises are shared with the principal
investigators.
Incentive program preferences
To assess preference for incentive design, research staff
describe two hypothetical financial incentive programs for
smoking cessation, and then ask which program the par-
ticipant prefers. One program uses goal-directed incen-
tives (incentives weighted toward use of evidence-based
therapies) and the other uses outcome-based incentives
(incentives for successful achievement of an outcome such
as successfully quitting) [5]. Total attainable incentives are
similar in both programs. These data inform hypotheses
regarding whether patients randomized to the incentive
arm will demonstrate different smoking cessation out-
comes depending on their prespecified (prerandomiza-
tion) program preference.
Oral Microbiome Substudy
The FIESTA Oral Microbiome Substudy aims to assess
whether smoking cessation changes oral microbiome
composition by comparing the oral microbiome of
smokers and nonsmokers longitudinally. The FIESTA
Oral Microbiome Substudy has four objectives. The first
objective is to investigate differences in the oral micro-
biomes of smokers versus nonsmokers at baseline. We
hypothesize that there will be significant, dose-related
differences. The second objective is to determine if
smoking is associated with changes in the oral micro-
biome longitudinally. We hypothesize that the oral
microbiomes of quitters will be most similar to non-
smokers at 12 months. The third objective is to identify
oral microbiome predictors of successful smoking cessa-
tion by comparing the baseline oral microbiome of
smokers who successfully quit to the baseline oral
microbiome of smokers who did not quit. We
hypothesize that there will be no specific patterns that
are predictive of success in smoking cessation. The
fourth objective is to determine if the oral microbiome
in smokers is associated with increased levels of oral
mutagens and carcinogens. We hypothesize that
smokers will have higher baseline levels of mutagens and
carcinogens and that quitters will have levels of muta-
gens and carcinogens comparable to nonsmokers after
12 months.
To achieve the objectives of the FIESTA Oral Micro-
biome Substudy, we enroll nonsmoking control partici-
pants matched to each FIESTA smoker based on the
criteria previously described. Saliva samples are collected
at baseline, 2 months, 6 months, and 12 months to
characterize the oral microbiome. Specimens are stored
in a freezer at approximately −78 °C in the Manhattan VA
until laboratory analysis is conducted. We complete an
Ames test and test for the carcinogens benzo-a-pyrine and
nicotine-derived nitrosamine ketone. This is a pilot
performed on a subset of participants. We also assess how
the oral flora metabolized carcinogens.
French et al. Trials          (2018) 19:646 Page 6 of 10
For data collection, each participant is asked to
complete an in-person survey at enrollment in addition
to follow-up interviews by phone at 2 months, 6 months,
and 12 months. These participants are also asked to pro-
vide saliva samples at these time points, with a $50 in-
centive payment at each follow-up time point. Letters
are mailed to participants 2 weeks before each follow-up
window as a reminder and to provide them with the op-
portunity to update their contact information.
Adverse events
At all scheduled contact between staff and participants,
patients are asked about any potential adverse events
that had occurred since enrollment or their most recent
follow-up assessment. This list of potential events in-
cludes violations of confidentiality, emergency room
visits without hospitalization, and suicidal ideation not
requiring intervention, as well as serious adverse events,
including death, life-threatening events, hospitalization,
and suicidal ideation requiring intervention. If a patient
experiences an adverse event, staff record: 1) event onset
date; 2) report date; 3) reporting staff member; 4) study
phase, i.e., prerandomization, in-treatment, or follow-up;
and 5) a detailed description of the adverse event, i.e.,
symptoms, course, duration, treatment, or cause of death
if known.
Data monitoring
The study coordinators generate reports for the principal
investigators on a monthly basis. These reports contain
a summary of enrollment, retention, participant with-
drawals, detailed descriptions of adverse events, and de-
tailed descriptions of protocol violations. Reports are
periodically submitted to the Institutional Review Board
(IRB) for continued review. The principal investigators
are notified within 24 h of recognition of any adverse
events. Serious adverse events are reported within 10
business days to the IRB.
Sample size
We will enroll 182 smokers and expect a 60% participa-
tion rate. In addition, we expect a 10–15% loss to
follow-up rate at 6 months. We consider an absolute dif-
ference of approximately 20% in smoking cessation rates
to be clinically substantial, where absolute difference
= (rate1 – rate2). Therefore, this sample size (91 patients
per arm) allows at least 80% power to detect a substan-
tial clinical difference in smoking cessation rates be-
tween the control group (enhanced usual care alone
arm) and intervention group (financial incentives plus
enhanced usual care arm) with α = 0.05.
Analytic plan
The primary outcome in this trial is the smoking cessa-
tion rate at 6 months. Secondary outcomes in this trial
include: 1) financial distress and security; 2) subjective
social status; 3) other substance use including alcohol;
and 4) quality of life. Chi-squared tests, t tests, and non-
parametric tests will be used to compare baseline char-
acteristics of patients to assess balance between the two
study arms. Multivariate analyses for longitudinal data
will include difference-in-difference models and Cox
proportional hazard models, and these models will in-
clude patient-level variables, area-based socioeconomic
factors, and hospital variables as covariates.
For the economic evaluation, we will estimate the re-
turn on investment of financial incentives intervention
from the perspective of the healthcare system (hospitali-
zations, ambulatory care, and medications) on a
per-patient basis. Costs will be determined by: 1) multi-
plying employee wages (based on United States Bureau
of Labor Statistics values) [35] by the estimated time
these personnel spend on smoking cessation care; 2)
using the Red Book to estimate NRT and other medica-
tion costs (based on average wholesale prices) [36]; and
3) estimating bulk purchase prices for other physical ma-
terials provided to smokers. The return on investment
will then be estimated using the difference between the
value of financial incentives provided to smokers and the
incremental healthcare costs or savings, comparing the
financial incentives plus enhanced usual care arm to the
enhanced usual care alone arm.
We will also estimate the cost-effectiveness of the fi-
nancial incentives intervention using the ratio of the dif-
ference in costs between the intervention group and
control group to the difference in quality of life and
smoking cessation rates between the intervention and
control groups [37]. We will perform nonparametric
bootstrapping with 1000 random samples to estimate
confidence intervals (CIs) for the cost-effectiveness ra-
tios and we will use the bias-corrected percentile
method described by Efron and others [38–40]. We will
consider recidivism rates of participants when estimating
the cost-effectiveness of the interventions in this trial.
Specifically, we anticipate that recidivism will reduce
cost-effectiveness by reducing the incremental benefits
of the intervention.
Discussion
Innovation
FIESTA is innovative for three main reasons. FIESTA is
the first randomized trial to test the effectiveness of fi-
nancial incentives in hospitalized patients. Previous
smoking cessation studies enrolling inpatient smokers
have utilized different intervention models, with
follow-up counseling after discharge being one of the
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most commonly used models. In a 2012 meta-analysis of
smoking cessation studies, the authors found that sup-
portive follow-up counseling for at least 1 month post-
discharge—provided by either nurses or trained
counselors—significantly increased smoking cessation
rates [41]. Other studies in this meta-analysis concluded
that adding NRT to intensive counseling increased
smoking cessation rates compared with intensive coun-
seling alone (risk ratio (RR) 1.54, 95% CI 1.34 to 1.79,
six trials). Because this meta-analysis largely examined
interventions incorporating intensive counseling, its re-
sults may not be generalizable to our study, which lever-
ages a more pragmatic model [41]. While FIESTA does
not formally incorporate 4 weeks of postdischarge
follow-up per se, it leverages a pragmatic framework by
building on Quitlines, an existing infrastructure for
evidence-based smoking cessation.
A second innovative characteristic of FIESTA is its for-
mal incorporation of an economic analysis to evaluate
return on investment. At the time of FIESTA’s design,
economic evaluations were uncommon in smoking ces-
sation trials of hospitalized patients. In FIESTA, this
economic evaluation explicitly addresses the issue of fi-
nancial sustainability of financial incentives for smoking
cessation.
A third innovative component of FIESTA is its incorp-
oration of behavioral economic concepts. While limited
in scope when considering the expansive number of
tools available in the behavioral economic literature, FI-
ESTA emphasizes the importance of providing payments
as soon as possible, so that participants could more
readily associate a payment with the behavior that trig-
gered it. Behavioral economists often cite hyperbolic dis-
counting as an explanation for why money received
immediately is perceived to be substantially more valu-
able than money received in the near future, even after
accounting for standard discounting. We also frame
feedback to participants in the incentive arm who did
not meet their goals using regret aversion by emphasiz-
ing what the participants would have received had they
met their goals [42, 43].
FIESTA also faces several challenges. Our patient
population consists largely of low-income participants
and they frequently face socioeconomic burdens (hous-
ing instability, substance abuse, etc.) that increase the
challenges associated with recruitment and retention.
With regard to recruitment, research staff often encoun-
ter barriers to recruitment that are inherent to the hos-
pital setting, such as surgical operations or procedures,
nurse or physician visits, family or friend visits, meals,
and uncertainty about postdischarge disposition. Conse-
quently, it is frequently difficult to screen and enroll eli-
gible patients prior to discharge. Moreover, in some
instances, the postdischarge disposition of participants
changes following enrollment, and the participants will in-
stead enter a rehabilitation program during which we are
unable to reach them. In addition, many participants use
prepaid cell phone plans that are restricted in the number
of available minutes per month, which likely reduces the
likelihood of successfully completing follow-up surveys or
scheduling saliva collection appointments with research
staff. Many participants also lack permanent home ad-
dresses and often change addresses depending on housing
or shelter availability, which likely decreases the probabil-
ity that participation letters or mailed reminders will reach
the intended participant.
Summary and significance
FIESTA is the first randomized trial of financial incen-
tives for smoking cessation in hospitalized patients, and
it focuses on hospitalized veterans. We anticipate that its
findings will have implications for our understanding of
the effectiveness of financial incentive interventions in
inpatient settings, the association of smoking cessation
with oral microbiome changes, and the design of smok-
ing cessation interventions in vulnerable hospitalized
populations.
Trial status
FIESTA began enrollment on 14 July 2015 and enroll-
ment is ongoing. The protocol version used was Version
1, dated 19 March 2015.
Additional file
Additional file 1: SPIRIT checklist. (DOC 125 kb)
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